Voyager Therapeutics to Present at Investor Conferences in October
October 03 2017 - 8:01AM
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene
therapy company developing life-changing treatments for severe
neurological diseases, today announced management presentations at
the upcoming investor conferences:
- Chardan Gene Therapy Conference, New York
CityDate: Tuesday, October 10,
2017Time: 9:00 a.m. EDTPanel
Members: Jane Henderson, chief financial officer and
senior vice president of corporate development and Bernard Ravina,
M.D., M.S., chief medical officer
- Jefferies Gene Technology Investor Summit,
New York CityDate: Thursday,
October 12, 2017Time: 3:30 p.m. EDTPanel
Members: Jane Henderson, chief financial officer and
senior vice president of corporate development and Dinah Sah,
Ph.D., chief scientific officer
Live-streaming webcasts of these presentations
can be accessed through the Investors & Media section of
Voyager’s website at www.voyagertherapeutics.com. The webcast
will be archived for 30 days after the live event concludes.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene
therapy company focused on developing life-changing treatments for
severe neurological diseases. Voyager is committed to advancing the
field of adeno-associated virus (AAV) gene therapy through
innovation and investment in vector engineering and optimization,
manufacturing and dosing and delivery techniques. Voyager’s
pipeline focuses on severe neurological diseases in need of
effective new therapies, including advanced Parkinson’s disease, a
monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia,
frontotemporal dementia, Alzheimer’s disease and severe, chronic
pain. Voyager has broad strategic collaborations with Sanofi
Genzyme, the specialty care global business unit of Sanofi, and the
University of Massachusetts Medical School. Founded by
scientific and clinical leaders in the fields of AAV gene therapy,
expressed RNA interference and neuroscience, Voyager Therapeutics
is headquartered in Cambridge, Massachusetts. For more
information, please visit www.voyagertherapeutics.com.
Investor Relations:
Matt Osborne
Head of Investor Relations & Corporate Communications
857-259-5353
mosborne@vygr.com
Media:
Katie Engleman
Pure Communications, Inc.
910-509-3977
Katie@purecommunicationsinc.com
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Sep 2023 to Sep 2024